• Explore /
  • Poster
  • / T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi).

T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi).

Abstract Poster

Authors

null

David B. Page

Memorial Sloan Kettering Cancer Center, New York, NY

David B. Page , Adi Diab , Jianda Yuan , Zhiwan Dong , Ryan Emerson , Harlan Robins , David Redmond , Chunjun Zhao , Zhenyu Mu , Phillip Wong , Stephen Barnett Solomon , Virgilio Sacchini , Monica Morrow , Edi Brogi , Sujata Patil , Jedd D. Wolchok , Clifford A. Hudis , Larry Norton , James Patrick Allison , Heather L. McArthur

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT01502592

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3021)

DOI

10.1200/jco.2014.32.15_suppl.3021

Abstract #

3021

Poster Bd #

13

Abstract Disclosures

Similar Posters

First Author: Elizabeth Anne Comen

First Author: Alexandre Reuben

Poster

2019 Genitourinary Cancers Symposium

Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.

Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.

First Author: Scott Williams

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).

Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).

First Author: John Yi